344,795 Shares in Amedisys, Inc. (NASDAQ:AMED) Purchased by Segantii Capital Management Ltd

Segantii Capital Management Ltd bought a new stake in Amedisys, Inc. (NASDAQ:AMED) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 344,795 shares of the health services provider’s stock, valued at approximately $32,776,000. Amedisys comprises approximately 1.7% of Segantii Capital Management Ltd’s holdings, making the stock its 14th biggest holding.

Several other hedge funds also recently bought and sold shares of AMED. Commonwealth Equity Services LLC grew its stake in shares of Amedisys by 2.9% in the third quarter. Commonwealth Equity Services LLC now owns 3,896 shares of the health services provider’s stock valued at $364,000 after buying an additional 110 shares in the last quarter. Xponance Inc. boosted its holdings in Amedisys by 3.2% in the third quarter. Xponance Inc. now owns 4,076 shares of the health services provider’s stock valued at $381,000 after purchasing an additional 125 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Amedisys by 12.7% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,893 shares of the health services provider’s stock valued at $550,000 after purchasing an additional 663 shares in the last quarter. ING Groep NV increased its stake in shares of Amedisys by 257.4% during the third quarter. ING Groep NV now owns 189,800 shares of the health services provider’s stock worth $17,727,000 after buying an additional 136,700 shares during the period. Finally, Olympiad Research LP increased its stake in shares of Amedisys by 94.9% during the third quarter. Olympiad Research LP now owns 15,968 shares of the health services provider’s stock worth $1,491,000 after buying an additional 7,777 shares during the period. Hedge funds and other institutional investors own 94.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on AMED shares. Royal Bank of Canada increased their price objective on shares of Amedisys from $97.00 to $100.00 and gave the company an “outperform” rating in a research report on Monday, March 25th. Raymond James reaffirmed a “market perform” rating on shares of Amedisys in a report on Tuesday, March 26th. StockNews.com upgraded Amedisys from a “hold” rating to a “buy” rating in a report on Saturday, May 4th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $101.00 price target on shares of Amedisys in a research note on Thursday, April 25th. Seven investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $100.80.

Amedisys Stock Performance

Shares of AMED stock traded up $0.47 during trading hours on Thursday, hitting $94.55. The stock had a trading volume of 462,638 shares, compared to its average volume of 277,434. The firm has a market capitalization of $3.09 billion, a PE ratio of -147.00, a PEG ratio of 3.43 and a beta of 0.84. The stock’s 50 day moving average is $92.32 and its 200 day moving average is $93.33. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.09 and a quick ratio of 1.09. Amedisys, Inc. has a twelve month low of $73.10 and a twelve month high of $96.44.

Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Wednesday, April 24th. The health services provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. The firm had revenue of $571.41 million for the quarter, compared to analyst estimates of $565.38 million. Amedisys had a positive return on equity of 12.85% and a negative net margin of 0.91%. The business’s revenue was up 2.7% on a year-over-year basis. During the same quarter last year, the company posted $1.00 earnings per share. As a group, research analysts forecast that Amedisys, Inc. will post 4.57 earnings per share for the current fiscal year.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.